MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
480.18
+4.98
+1.05%
After Hours: 485.00 +4.82 +1.00% 19:55 06/25 EDT
OPEN
475.11
PREV CLOSE
475.20
HIGH
486.49
LOW
473.50
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
507.92
52 WEEK LOW
362.50
MARKET CAP
121.87B
P/E (TTM)
28.47
1D
5D
1M
3M
1Y
5Y
1D
Raymond James Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
TipRanks · 23h ago
Health Care Select Sector SPDR Fund Experiences Big Outflow
NASDAQ · 1d ago
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
Seeking Alpha · 1d ago
Changan Huitong-backed Mico Pharma jumps 103% in Hong Kong debut after HKD 1.06 billion IPO
PUBT · 1d ago
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX)
TipRanks · 1d ago
Shaanxi fund-backed Microcure Pharma lists in Hong Kong under Chapter 18A rules
PUBT · 1d ago
Vertex EVP, CMO Carmen Bozic sells 1,020 Vertex shares for $471,413.4
PUBT · 2d ago
Biotech breakout: iShares Biotechnology ETF hits all-time high
Seeking Alpha · 2d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Webull offers Vertex Pharmaceuticals Inc stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.